PP
AKBA icon

PDS Planning’s Akebia Therapeutics AKBA Stock Holding History

PDS Planning’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.5K Hold
50,000
– – ﹤0.01% 553
2025
Q4 		$80.5K Hold
50,000
– – 0.01% 543
2025
Q3 		$137K Hold
50,000
– – 0.01% 522
2025
Q2 		$182K Buy
50,000
+5,000
+11% +$13.7K 0.01% 489
2025
Q1 		$86.4K Buy
45,000
+30,000
+200% +$61.2K 0.01% 458
2024
Q4 		$28.5K Buy
+15,000
New +$26K ﹤0.01% 442

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PDS Planning's AKBA Position: Q1 2026 in Review

PDS Planning held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 50,000 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #553.

PDS Planning first reported a position in AKBA in Q4 2024 and has held it in 6 quarters since. The position peaked at $182K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • PDS Planning held 50,000 shares of Akebia Therapeutics worth $69.5K as of Q1 2026.
  • PDS Planning left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of PDS Planning's portfolio in Q1 2026, its #553 holding.
  • PDS Planning first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • PDS Planning's Akebia Therapeutics position peaked at $182K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.